Answer:
The expiration of patents for two of the statin drugs in 2006 likely had a significant impact on the entire category of statin drugs. With the expiration of the patents, generic versions of the two drugs became available, which likely led to increased competition and lower prices for those specific drugs. This, in turn, may have led some patients to switch from other statins to the newly available generic versions, causing a decrease in sales for the branded drugs whose patents were still in effect.
Additionally, the availability of generic versions of the drugs may have led to increased overall usage of statins, as patients who previously could not afford the branded drugs may have been able to access the generic versions. This could have increased competition among all statin drugs, leading to lower prices and increased usage overall.
Overall, the expiration of patents for two statin drugs in 2006 likely had a significant impact on the entire category of statin drugs, leading to increased competition, lower prices, and potentially increased overall usage.